Teva Pharmaceutical Industries Limited (TLV:TEVA)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
6,186.00
+211.00 (3.53%)
Feb 20, 2025, 5:24 PM IDT
30.23%
Market Cap 68.37B
Revenue (ttm) 60.26B
Net Income (ttm) -5.97B
Shares Out n/a
EPS (ttm) -5.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,497,360
Average Volume 2,226,944
Open 6,082.00
Previous Close 5,975.00
Day's Range 6,071.00 - 6,252.00
52-Week Range 4,671.00 - 8,431.00
Beta 0.71
RSI 40.02
Earnings Date Jan 29, 2025

About TLV:TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]

Sector Healthcare
Founded 1901
Employees 35,686
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol TEVA
Full Company Profile

Financial Performance

In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.

Financial numbers in USD Financial Statements

News

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn's Disease

New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on cli...

22 hours ago - GlobeNewsWire

Final Trade: TEVA, JNJ, TJX, BABA

The final trades of the day with the Fast Money traders.

1 day ago - CNBC Television

Final Trade: TEVA, JNJ, TJX, BABA

The final trades of the day with the Fast Money traders.

1 day ago - CNBC

Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States.

1 day ago - Reuters

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

PARSIPPANY, N.J. and REYKJAVÍK, Iceland, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: AL...

1 day ago - GlobeNewsWire

Teva Pharmaceutical Industries Ltd (TEVA) and Alvotech Announce FDA Review of Biosimilar Application

Teva Pharmaceutical Industries Ltd (TEVA) and Alvotech Announce FDA Review of Biosimilar Application

3 days ago - GuruFocus

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO)

TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live webcast at 8 am E.T. on Mon...

4 days ago - Financial Post

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)

TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live webcast at 8 am E.T. on Mo...

4 days ago - GlobeNewsWire

Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst

On Tuesday, Axsome Therapeutics Inc (NASDAQ: AXSM) reported fourth-quarter 2024 revenues of $118.77 million, up from $71.53 million a year ago, beating the consensus of $117.64 million. Auvelity (ora...

4 days ago - Benzinga

FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea

Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 treatment for eye disorders, which could compete with Regeneron Pharmaceuticals’ ...

4 days ago - Investopedia

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for...

4 days ago - GlobeNewsWire

Teva Pharm CEO calls for faster US generic drug approvals

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding freezes, the CEO of Israel's Teva Pharmaceutical Industries said on Monday.

5 days ago - Reuters

Stanley Druckenmiller's Strategic Moves: A Closer Look at Teva Pharmaceutical Industries Ltd

Stanley Druckenmiller's Strategic Moves: A Closer Look at Teva Pharmaceutical Industries Ltd

8 days ago - GuruFocus

Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade

Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's Auvelity ...

11 days ago - Seeking Alpha

Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bearish stance on Teva Pharmaceutical Indus (NYSE: TEVA). And retail traders should know. We noticed this today when the trades showed up on public...

12 days ago - Benzinga

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval. Latest Ratings for ... Full story available ...

12 days ago - Benzinga

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

On Monday, Axsome Therapeutics, Inc. AXSM signed a settlement agreement with Teva Pharmaceuticals Inc TEVA.

12 days ago - Benzinga

Axsome settles Auvelity patent litigation with Teva

Axsome Therapeutics (AXSM) stock rallied 15% on news the company has settled patent litigation with Teva (TEVA) over a proposed generic version of Auvelity. Read more here.

12 days ago - Seeking Alpha

Teva Pharmaceuticals reports completion of phase 3 trial for Olanzapine LAI in Schizophrenia

Update on the completion of pivotal phase 3 trial for olanzapine Long-Acting Injectable in schizophrenia by Medincell's partner Teva Pharmaceuticals.

12 days ago - Seeking Alpha

Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): ACCESS HERE THE FULL PRESS RELEASE.

12 days ago - Business Wire

Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight

Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight

15 days ago - GuruFocus

Teva Pharmaceutical announces mixed shelf offering

Learn about the securities offered by Teva Pharmaceutical, including American Depositary Shares, debt securities, and more.

15 days ago - Seeking Alpha